Ginkgo Bioworks downgraded by Goldman with a new price target

6/2/23 7:18:26 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Goldman downgraded Ginkgo Bioworks from Neutral to Sell and set a new price target of $1.25 from $3.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DNA

Date	Price Target	Rating	Analyst
5/15/2024		Neutral → Sell	BTIG Research
5/10/2024		Mkt Perform → Underperform	William Blair
11/14/2023	$3.50 → $2.50	Outperform → Mkt Perform	Raymond James
11/9/2023		Buy → Neutral	BTIG Research
6/2/2023	$3.00 → $1.25	Neutral → Sell	Goldman
5/11/2023		Outperform → Mkt Perform	William Blair
11/29/2022	$6.00	Buy	Berenberg
10/4/2022	$5.00	Equal-Weight	Morgan Stanley